NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Price Target & More

$2.60 -0.05 (-1.89 %)

(As of 04/20/2018 02:12 PM ET)

Previous Close$2.65

Today's Range$2.56 - $2.67

52-Week Range$0.57 - $4.24

Volume968,544 shs

Average Volume1.86 million shs

Market Capitalization$328.07 million

P/E Ratio-16.25

Dividend YieldN/A

Beta1.32

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:AVEO

CUSIP05358810

Webwww.aveooncology.com

Phone617-588-1960

Debt

Debt-to-Equity Ratio-0.45%

Current Ratio1.56%

Quick Ratio1.56%

Price-To-Earnings

Trailing P/E Ratio-16.25

Forward P/E Ratio-9.63

P/E GrowthN/A

Sales & Book Value

Annual Sales$7.58 million

Price / Sales40.77

Cash FlowN/A

Price / CashN/A

Book Value($0.34) per share

Price / Book-7.65

Profitability

EPS (Most Recent Fiscal Year)($0.16)

Net Income$-65,020,000.00

Net Margins-857.96%

Return on EquityN/A

Return on Assets-41.17%

Miscellaneous

Employees19

Outstanding Shares118,870,000

How to Become a New Pot Stock Millionaire

AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings data on Thursday, May, 4th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.00. The biopharmaceutical company earned $2.53 million during the quarter. View AVEO Pharmaceuticals' Earnings History.

What price target have analysts set for AVEO?

4 brokers have issued 1-year price objectives for AVEO Pharmaceuticals' shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $4.1667 in the next twelve months. View Analyst Ratings for AVEO Pharmaceuticals.

Who are some of AVEO Pharmaceuticals' key competitors?

Some companies that are related to AVEO Pharmaceuticals include Ziopharm Oncology (ZIOP), Rhythm Pharmaceuticals (RYTM), Arrowhead Pharmaceuticals (ARWR), BeyondSpring (BYSI), Geron (GERN), Odonate Therapeutics (ODT), Reata Pharmaceuticals (RETA), Five Prime Therapeutics (FPRX), Clementia Pharmaceuticals (CMTA), Kura Oncology (KURA), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), AC Immune (ACIU), Rigel Pharmaceuticals (RIGL), Achaogen (AKAO), TiGenix - American Depositary Shares (TIG), Akebia Therapeutics (AKBA) and Dicerna Pharmaceuticals (DRNA).

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:

Mr. Michael P. Bailey, Pres, CEO & Director (Age 53)
Dr. Michael N. Needle M.D., Chief Medical Officer (Age 58)
Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
Dr. Emile Farhan Ph.D., VP of Technical Operations
Ms. Karuna Rubin J.D., VP of Legal Affairs and Corp. Sec.

Has AVEO Pharmaceuticals been receiving favorable news coverage?

Press coverage about AVEO stock has trended somewhat negative this week, Accern reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of -0.03 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 44.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $2.62.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $328.07 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]

MarketBeat Community Rating for AVEO Pharmaceuticals (AVEO)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		225 (Vote Outperform)
Underperform Votes:		223 (Vote Underperform)
Total Votes:		448

MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.

AVEO Pharmaceuticals (NASDAQ:AVEO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for AVEO Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.1667, suggesting that the stock has a possible upside of 60.26%. The high price target for AVEO is $5.00 and the low price target for AVEO is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$4.1667	$4.1667	$4.1667	$3.75
Price Target Upside:	60.26% upside	34.41% upside	34.41% upside	5.06% downside

AVEO Pharmaceuticals (NASDAQ:AVEO) Consensus Price Target History

Price Target History for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ:AVEO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/16/2018	B. Riley	Reiterated Rating	Buy	$5.00	High
10/6/2017	Seaport Global Securities	Reiterated Rating	Buy		N/A
8/28/2017	Piper Jaffray	Boost Price Target	Overweight	$3.80 -> $4.50	High
7/13/2017	FBR & Co	Reiterated Rating	Outperform	$3.00	High

(Data available from 4/20/2016 forward)

AVEO Pharmaceuticals (NASDAQ:AVEO) Earnings History and Estimates Chart

Earnings by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ:AVEO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.26)
2019 EPS Consensus Estimate: ($0.18)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.06)	($0.06)	($0.06)
Q2 2018	1	($0.06)	($0.06)	($0.06)
Q3 2018	1	($0.07)	($0.07)	($0.07)
Q4 2018	1	($0.07)	($0.07)	($0.07)
Q1 2019	1	($0.05)	($0.05)	($0.05)
Q2 2019	1	($0.05)	($0.05)	($0.05)
Q3 2019	1	($0.04)	($0.04)	($0.04)
Q4 2019	1	($0.04)	($0.04)	($0.04)

AVEO Pharmaceuticals (NASDAQ AVEO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/7/2017	Q3 2017	($0.05)	($0.02)	$6.50 million	$4.61 million	View	N/A
8/9/2017	Q2 2017	($0.10)	($0.08)	$4.00 million	$0.35 million	View	N/A
5/4/2017	Q1 2017	($0.12)	($0.1160)		$2.53 million	View	N/A
3/22/2017	Q4 2016	($0.09)	($0.11)		$0.13 million	View	N/A
11/4/2016	Q3 2016	($0.1150)	($0.07)		$0.99 million	View	N/A
8/4/2016	Q2 2016	($0.14)	($0.13)		$0.19 million	View	N/A
5/10/2016	Q1	($0.12)	($0.13)	$1.00 million	$1.20 million	View	N/A
3/15/2016	Q415	($0.04)	($0.11)		$3.60 million	View	N/A
11/9/2015	Q315	($0.09)	$0.14		$15.16 million	View	N/A
8/10/2015	Q2	($0.16)	($0.10)		$0.13 million	View	Listen
5/7/2015	Q115	($0.27)	($0.21)		$0.13 million	View	N/A
3/6/2015	Q314	($0.28)	($0.27)		$0.12 million	View	Listen
11/5/2014	Q3 2014	($0.27)	($0.28)	$0.33 million	$0.87 million	View	N/A
8/11/2014	Q214	($0.38)	($0.35)	$0.35 million	$1.85 million	View	N/A
5/7/2014	Q1 2014	($0.33)	($0.12)	$0.38 million	$15.29 million	View	N/A
3/13/2014	Q413	($0.33)	($0.32)	$0.14 million	$0.3230 million	View	Listen
11/4/2013	Q313	($0.47)	($0.47)	$0.23 million	$0.32 million	View	N/A
8/1/2013	Q213	($0.56)	($0.62)	$4.30 million	$0.32 million	View	N/A
4/29/2013	Q1 2013	($0.72)	($0.69)	$2.52 million	$0.3230 million	View	Listen
2/13/2013	Q4 2012	($0.77)	($0.49)	$14.49 million	$15.53 million	View	N/A
10/30/2012	Q312	($0.87)	($0.69)	$6.57 million	$1.02 million	View	N/A
8/2/2012		($0.82)	($0.68)			View	N/A
5/3/2012		($0.78)	($0.77)			View	N/A
2/14/2012		($0.64)	($0.58)			View	N/A
11/2/2011		($0.46)	($0.55)			View	N/A
7/28/2011		($0.80)	($0.16)			View	N/A
4/28/2011	Q1 2011	($0.57)	$2.28			View	N/A
2/16/2011	Q4 2010	($0.64)	($0.30)			View	N/A
11/4/2010	Q3 2010	($0.62)	($0.60)			View	N/A
7/29/2010	Q2 2010	($0.35)	($0.50)			View	N/A
4/29/2010	Q1 2010	($0.81)	($2.27)			View	N/A

(Earnings results data provided by Zacks Investment Research)

AVEO Pharmaceuticals (NASDAQ:AVEO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 51.58%

Insider Trading History for AVEO Pharmaceuticals (NASDAQ:AVEO)

Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/10/2018	Peter J Barris	Major Shareholder	Buy	920,976	$2.30	$2,118,244.80
4/6/2018	Ravi Viswanathan	Major Shareholder	Buy	685,676	$2.24	$1,535,914.24
3/28/2017	Equity Opportunities Iv Growth	Major Shareholder	Buy	6,000,000	$0.50	$3,000,000.00
1/16/2015	Matthew D Dallas	VP	Sell	3,075	$0.82	$2,521.50
1/7/2015	Michael P Bailey	CEO	Sell	4,484	$0.80	$3,587.20
1/30/2014	Joseph Vittiglio	SVP	Sell	5,430	$1.64	$8,905.20	34,121
3/14/2013	David Brannon Johnston	CFO	Sell	1,061	$7.34	$7,787.74
3/7/2013	Henri A Termeer	Director	Buy	55,499	$6.73	$373,508.27
12/13/2012	Ngoc Tuan Ha	CEO	Buy	75,000	$6.65	$498,750.00
12/13/2012	Robert C Young	Director	Buy	2,371	$6.78	$16,075.38
12/3/2012	Robert C Young	Director	Buy	1,250	$6.41	$8,012.50
9/13/2012	David Brannon Johnston	CFO	Sell	1,386	$10.60	$14,691.60
8/8/2012	Robert C Young	Director	Buy	1,000	$8.63	$8,630.00

(Data available from 1/1/2013 forward)

AVEO Pharmaceuticals (NASDAQ AVEO) News Headlines

Source:

Date	Headline
	SEC seeks to block ex-Aveo CFO's testimony about consulting counsel www.reuters.com - April 19 at 8:16 AM
	AVEO Pharmaceuticals (AVEO) Upgraded to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 16 at 9:17 PM
	AVEO Down 7.7% Since Earnings Report: Can It Rebound? finance.yahoo.com - April 12 at 5:39 PM
	AVEO Pharmaceuticals (AVEO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow seekingalpha.com - April 11 at 5:32 PM
	AVEO Pharmaceuticals' (AVEO) Buy Rating Reiterated at Piper Jaffray www.americanbankingnews.com - April 10 at 10:31 PM
	Insider Buying: AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Acquires 685,676 Shares of Stock www.americanbankingnews.com - April 10 at 7:30 PM
	Peter J. Barris Purchases 920,976 Shares of AVEO Pharmaceuticals, Inc. (AVEO) Stock www.americanbankingnews.com - April 10 at 7:12 PM
	Why AVEO Oncology Jumped Higher Today finance.yahoo.com - April 9 at 5:22 PM
	Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO) finance.yahoo.com - April 5 at 10:10 AM
	Zacks: Brokerages Anticipate AVEO Pharmaceuticals, Inc. (AVEO) to Post -$0.07 EPS www.americanbankingnews.com - April 2 at 9:12 AM
	AVEO Pharmaceuticals (AVEO) Downgraded by BidaskClub www.americanbankingnews.com - March 30 at 9:17 AM
	AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - March 30 at 1:34 AM
	AVEO Pharmaceuticals (AVEO) Lifted to Hold at Zacks Investment Research www.americanbankingnews.com - March 29 at 11:18 PM
	AVEO Pharmaceuticals (AVEO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow seekingalpha.com - March 29 at 5:30 PM
	AVEO Pharmaceuticals (AVEO) Rating Reiterated by B. Riley www.americanbankingnews.com - March 28 at 12:58 PM
	AVEO Pharmaceuticals (AVEO) Upgraded to "Sell" by BidaskClub www.americanbankingnews.com - March 26 at 5:58 PM
	AVEO Pharmaceuticals (AVEO) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - March 25 at 12:52 AM
	AVEO Pharmaceuticals (AVEO) Rating Increased to Sell at BidaskClub www.americanbankingnews.com - March 24 at 10:58 AM
	Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock finance.yahoo.com - March 23 at 5:42 PM
$AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC$	AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC finance.yahoo.com - March 21 at 5:38 PM
	AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down - Yahoo Finance finance.yahoo.com - March 16 at 8:19 AM
	-$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter www.americanbankingnews.com - March 16 at 7:33 AM
	Q3 2018 EPS Estimates for AVEO Pharmaceuticals, Inc. Cut by B. Riley (AVEO) www.americanbankingnews.com - March 15 at 8:15 AM
	AVEO Pharmaceuticals, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.05) Per Share (AVEO) www.americanbankingnews.com - March 14 at 12:56 PM
	BRIEF-Aveo Quarterly Loss Per Share $0.08 www.reuters.com - March 13 at 7:17 PM
	AVEO Pharmaceuticals (AVEO) Q4 Loss Wider, Revenues Miss finance.yahoo.com - March 13 at 7:17 PM
	AVEO Reports Full Year 2017 Financial Results and Provides Business Update finance.yahoo.com - March 13 at 8:25 AM
	AVEO posts 4Q profit finance.yahoo.com - March 13 at 8:25 AM
	Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of AVEO ... - PR Newswire (press release) www.prnewswire.com - March 9 at 8:20 AM
	AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store? www.msn.com - March 6 at 5:41 PM
	AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store? finance.yahoo.com - March 6 at 5:41 PM
	AVEO Oncology to Present at the Cowen and Company 38th Annual Health Care Conference finance.yahoo.com - March 6 at 8:15 AM
	Prosight Management LP Purchases New Holdings in AVEO Pharmaceuticals, Inc. (AVEO) www.americanbankingnews.com - March 5 at 2:54 PM
	AVEO Pharmaceuticals, Inc. (AVEO) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - March 5 at 1:30 AM
	Emory University Acquires Shares of 602,883 AVEO Pharmaceuticals, Inc. (AVEO) www.americanbankingnews.com - March 4 at 3:02 PM
	EAM Investors LLC Sells 158,839 Shares of AVEO Pharmaceuticals, Inc. (AVEO) www.americanbankingnews.com - March 3 at 5:40 AM
	Zai Lab (ZLAB) vs. AVEO Pharmaceuticals (AVEO) Head-To-Head Analysis www.americanbankingnews.com - February 12 at 11:36 AM
	Ex-Aveo Pharmaceuticals exec avoids max penalty in SEC fraud case www.reuters.com - February 10 at 9:43 AM
	AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - February 8 at 1:32 AM
	AVEO Announces Appointment of John H. Johnson to Board of Directors finance.yahoo.com - February 2 at 9:19 AM
	How Much is AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO Getting Paid? finance.yahoo.com - January 26 at 9:08 AM
	Biotech Forum Daily Digest For January 21st - Seeking Alpha seekingalpha.com - January 24 at 8:06 AM
	Blog Exposure - AVEO Pharma Presents Data from Phase-1b/2 Study of Tivozanib in Patients with Advanced HCC finance.yahoo.com - January 23 at 5:26 PM
	Ex-Aveo Pharmaceuticals exec fights SEC 'draconian' penalty request www.reuters.com - January 18 at 4:24 PM
	AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Recommendation of "Hold" from Brokerages www.americanbankingnews.com - January 14 at 1:32 AM
	Here's Why AVEO Oncology Rose as Much as 13.7% Today - Motley Fool www.fool.com - January 13 at 3:39 PM
	Here's Why AVEO Oncology Rose as Much as 13.7% Today finance.yahoo.com - January 13 at 11:05 AM
	AVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 4 at 11:11 AM
	SEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals exec www.reuters.com - January 2 at 9:13 PM
	AVEO Oncology Announces Refinanced Debt Facility finance.yahoo.com - January 2 at 9:13 PM

AVEO Pharmaceuticals (NASDAQ:AVEO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

AVEO Pharmaceuticals (NASDAQ:AVEO) Income Statement, Balance Sheet and Cash Flow Statement

AVEO Pharmaceuticals (NASDAQ AVEO) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff